23andMe Lays Off 40% of Staff, Shuts Drug Development Business – The Wall Street Journal

  1. 23andMe Lays Off 40% of Staff, Shuts Drug Development Business  The Wall Street Journal
  2. 23andMe cuts 40% of its workforce, discontinues all therapy programs  CNN
  3. The end of 23andMe’s drug discovery dream  STAT
  4. 23andMe to slash 40% of its workforce, end therapeutics program to cut costs  MarketWatch
  5. 23andMe to shut down its therapeutics division  Endpoints News